Investigating anti-neuroinflammatory therapeutics for polysubstance use disorders - the ongoing opioid crisis, exacerbated by synthetic opioids like fentanyl, has been further complicated by rising…
Active Project Grant Awarded Last action
- Award ID
- R16GM159685
- Recipient
-
East Tennessee State University UEI V5LLVC627U34 Part of Board Of Regents Tennessee
- Awarding agency
-
National Institute of General Medical Sciences
National Institutes of Health, Department of Health and Human Services
- Obligated
- $283,964
Award facts
- Assistance listing
- 93.859 Biomedical Research and Research Training
- Completion date 29% complete
- Place of performance
- Johnson City, TN 37614, USA
Award details come from USAspending.gov.
Description
Investigating anti-neuroinflammatory therapeutics for polysubstance use disorders - the ongoing opioid crisis, exacerbated by synthetic opioids like fentanyl, has been further complicated by rising CO-use of stimulants such as methamphetamine. Despite the increasing prevalence of polysubstance use, current research largely focuses on single-drug models, limiting understanding and treatment options for polysubstance use disorders. Methamphetamine and fentanyl both induce neuroinflammation, but the combined effects of these CO-used drugs on neuroinflammation and related behaviors remain unexplored. This project aims to address this GAP by investigating the functional significance and mechanism of polysubstance-induced neuroinflammation utilizing a novel rodent model of polysubstance dependence and withdrawal using CO- administered fentanyl and methamphetamine, with particular focus on the pro-inflammatory cytokine tumor necrosis factor-alpha (tnfα) and the neuropeptide hypocretin/orexin (hcrt). Hcrt influences a wide array of physiological functions, including those relevant to drug dependence and neuroinflammation, although the function of hcrt in drug-induced neuroinflammation is not yet well-understood. The overarching hypothesis is that during polysubstance withdrawal, hcrt functions as a pro-inflammatory agent in withdrawal-sensitive brain regions of the extended amygdala and the dorsal hypothalamus, contributing to neuroinflammation (including increases in tnfα) associated with polysubstance dependence. Aim 1 will determine tnfα's role in motivated polysubstance use and stress-induced reinstatement of drug-seeking using neuropharmacological techniques with a small-molecule tnfα-inhibitor. Aim 2 will define the role of hcrt signaling on polysubstance-induced neuroinflammation by measuring cytokine response to hcrt manipulations in polysubstance dependent rats. Findings from this research could significantly advance our understanding of the neuroimmune mechanisms driving polysubstance dependence and lead to the development of more effective treatments for addiction. Students will play an integral role in conducting hands-on, rigorous research as aligned with current NIH priorities and under the direct supervision of the PI and a team of collaborators.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $141,864 | |
| Original award | $142,100 |
Quick answers
Who received award R16GM159685?
R16GM159685 was awarded to East Tennessee State University by National Institute of General Medical Sciences (National Institutes of Health) on September 1, 2025.
How much is award R16GM159685 worth?
$283,964 has been obligated on R16GM159685.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award